Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772948 | 1.00 | RAPGEF4 (0.57) | RAPGEF4MAPTLMNAGAAMEN1 | |
| SCHEMBL22092711 | 0.86 | POLB (0.55) | RAPGEF4MAPTLMNAGAAMEN1 | |
| SCHEMBL29494990 | 0.86 | POLB (0.55) | RAPGEF4MAPTLMNAGAAMEN1 | |
| SCHEMBL2775637 | 0.82 | RAPGEF4 (0.54) | RAPGEF4MAPTLMNAMEN1KMT2A | |
| SCHEMBL22092710 | 0.79 | RAPGEF4 (0.57) | RAPGEF4MAPTMEN1KMT2AHTT | |
| SCHEMBL29494963 | 0.79 | RAPGEF4 (0.57) | RAPGEF4MAPTMEN1KMT2AHTT | |
| SCHEMBL22092694 | 0.78 | RAPGEF4 (0.56) | RAPGEF4MEN1KMT2AHTTKDR | |
| SCHEMBL29494936 | 0.78 | RAPGEF4 (0.56) | RAPGEF4MEN1KMT2AHTTKDR | |
| SCHEMBL2773336 | 0.77 | POLB (0.46) | MAPTMEN1KMT2AMAPK1TP53 | |
| SCHEMBL2772692 | 0.75 | POLB (0.49) | MAPTLMNAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | claimed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | claimed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | claimed |
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPDRN PHSTMS D.S.S. (FR) | 2010-07-08 | — | — | US | disclosed |
| EP-2178848-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009034258-A1 | TRI-AMINO-PYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173910-A1 | TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS | CDC25B, CDC25A, CDC25C | RAPGEF4 1886/4885MAPT 4215/4885LMNA 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.